
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): 11/07/2013

Dynavax Technologies Corporation

(Exact name of registrant as specified in its charter)

Commission File Number: 001-34207

Delaware
(State or other jurisdiction of
incorporation)

33-0728374
(IRS Employer
Identification No.)

2929 Seventh Street, Suite 100
Berkeley, CA 94710-2753
(Address of principal executive offices, including zip code)

(510) 848-5100
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 2.02. Results of Operations and Financial Condition

On November 7, 2013, Dynavax Technologies Corporation ("Dynavax") issued a press release announcing its financial results for the third quarter ended September 30, 2013. A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.

The information with respect to item 2.02 in this current report and its accompanying exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this current report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Dynavax, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits. The following exhibit is furnished herewith:

99.1 Press Release, dated November 7, 2013 titled "Dynavax Reports Third Quarter 2013 Financial Results."

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dynavax Technologies Corporation

Date: November 07, 2013

By: /s/ Michael S. Ostrach

Michael S. Ostrach
Vice President

EXHIBIT INDEX

Exhibit No.	Description
EX-99.1	DYNAVAX REPORTS THIRD QUARTER 2013 FINANCIAL RESULTS

Contacts:
Michael Ostrach
Vice President and Chief
Business Officer
510-665-7257
mostrach@dynavax.com

DYNAVAX REPORTS THIRD QUARTER 2013 FINANCIAL RESULTS

BERKELEY, CA - November 7, 2013 - Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter ended September 30, 2013. The Company had \$76.5 million in cash, cash equivalents and marketable securities as of September 30, 2013, compared to \$125.1 million at December 31, 2012.

For both quarters ended September 30, 2013 and 2012, Dynavax reported total revenues of \$2.9 million. Total revenues for the nine months ended September 30, 2013 were \$8.4 million compared to \$7.9 million for the same period in 2012.

General and administrative expenses for the quarter ended September 30, 2013 were \$5.8 million compared to \$7.1 million for the third quarter of 2012. For the nine months ended September 30, 2013, general and administrative expenses were \$22.2 million compared to \$18.9 million for the same period in 2012. This increase was due to one-time cash and non-cash stock-based severance costs of \$2.0 million and \$7.5 million, respectively, for the third quarter and nine month period of 2013. General and administrative expenses other than these organizational transition costs decreased by 49% during the third quarter and 24% for the nine month period of 2013.

Research and development expenses for the quarter ended September 30, 2013 were \$11.8 million compared to \$12.9 million for the third quarter of 2012. For the nine months ended September 30, 2013, research and development expenses were \$38.7 million compared to \$36.6 million for the same period in 2012. This increase was due primarily to manufacturing activities and expenses related to the supply of HEPLISAV™.

On October 30, 2013, the Company sold 79,570,000 shares of our common stock at a price of \$1.075 per share and 43,430 shares of the Company's Series B Convertible Preferred Stock (Series B) for a price of \$1,075.00 per share, in separate, concurrent underwritten public offerings. The sale of the common stock and Series B resulted in aggregate net proceeds to us of approximately \$125 million after deducting estimated commissions and offering expenses.

About Dynavax

Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases and cancer. The Company's lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine. For more information visit www.dynavax.com.

- tables to follow -

DYNAVAX TECHNOLOGIES CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)

	Three Months Ended		Nine Months Ended	
	<u>September 30,</u>		<u>September 30,</u>	
	<u>2013</u>	<u>2012</u>	<u>2013</u>	<u>2012</u>
Revenues:				
Collaboration revenue	\$ 1,110	\$ 1,050	\$ 3,349	\$ 3,602
Grant revenue	1,700	1,219	3,855	3,188
Service and license revenue	<u>117</u>	<u>605</u>	<u>1,200</u>	<u>1,118</u>
Total revenues	2,927	2,874	8,404	7,908

Operating expenses:				
Research and development	11,770	12,850	38,739	36,631
General and administrative	5,807	7,121	22,243	18,871
Unoccupied facility expense	<u>918</u>	=	<u>918</u>	=
Total operating expenses	<u>18,495</u>	<u>19,971</u>	<u>61,900</u>	<u>55,502</u>
Loss from operations	(15,568)	(17,097)	(53,496)	(47,594)
Interest income	37	91	163	208
Interest expense	(24)	(589)	(83)	(1,765)
Other income (expense)	<u>(120)</u>	<u>(196)</u>	<u>(248)</u>	<u>(255)</u>
Net loss	<u>\$ (15,675)</u>	<u>\$ (17,791)</u>	<u>\$ (53,664)</u>	<u>\$ (49,406)</u>
Basic and diluted net loss per share	<u>\$ (0.09)</u>	<u>\$ (0.10)</u>	<u>\$ (0.29)</u>	<u>\$ (0.30)</u>
Shares used to compute basic and diluted net loss per share	<u>183,022</u>	<u>177,870</u>	<u>182,960</u>	<u>167,039</u>

DYNAVAX TECHNOLOGIES CORPORATION
SELECTED CONSOLIDATED BALANCE SHEET DATA

(In thousands)

(Unaudited)

	<u>September 30,</u> <u>2013</u>	<u>December 31,</u> <u>2012</u>
Assets		
Cash, cash equivalents and marketable securities	\$ 76,474	\$ 125,130
Property and equipment, net	8,454	7,965
Goodwill	2,532	2,475
Other assets	<u>4,238</u>	<u>4,182</u>
Total assets	<u>\$ 91,698</u>	<u>\$ 139,752</u>
Liabilities and stockholders' equity		
Deferred revenues	\$ 8,877	\$ 12,068
Other liabilities	<u>10,425</u>	<u>12,858</u>
Total liabilities	19,302	24,926

Stockholders' equity	<u>72,396</u>	<u>114,826</u>
Total liabilities and stockholders' equity	<u>\$ 91,698</u>	<u>\$ 139,752</u>

###